Elusys’ Anthim Dramatically Improves Survival of Animals Treated After Active Anthrax Infection

Media Center PRESS RELEASE 2008 ELUSYS’ ANTHIM™ DRAMATICALLY IMPROVES SURVIVAL OF ANIMALS TREATED AFTER ACTIVE ANTHRAX INFECTION Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate Study Pine Brook, NJ – April 22, 2008 – Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, […]